首页> 美国卫生研究院文献>Oncotarget >RWCFusion: identifying phenotype-specific cancer driver gene fusions based on fusion pair random walk scoring method
【2h】

RWCFusion: identifying phenotype-specific cancer driver gene fusions based on fusion pair random walk scoring method

机译:RWCFusion:基于融合对随机游动评分法识别表型特异性癌症驱动基因融合

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

While gene fusions have been increasingly detected by next-generation sequencing (NGS) technologies based methods in human cancers, these methods have limitations in identifying driver fusions. In addition, the existing methods to identify driver gene fusions ignored the specificity among different cancers or only considered their local rather than global topology features in networks. Here, we proposed a novel network-based method, called RWCFusion, to identify phenotype-specific cancer driver gene fusions. To evaluate its performance, we used leave-one-out cross-validation in 35 cancers and achieved a high AUC value 0.925 for overall cancers and an average 0.929 for signal cancer. Furthermore, we classified 35 cancers into two classes: haematological and solid, of which the haematological got a highly AUC which is up to 0.968. Finally, we applied RWCFusion to breast cancer and found that top 13 gene fusions, such as BCAS3-BCAS4, NOTCH-NUP214, MED13-BCAS3 and CARM-SMARCA4, have been previously proved to be drivers for breast cancer. Additionally, 8 among the top 10 of the remaining candidate gene fusions, such as SULF2-ZNF217, MED1-ACSF2, and ACACA-STAC2, were inferred to be potential driver gene fusions of breast cancer by us.
机译:尽管基于下一代测序(NGS)技术的人类癌症中越来越多地检测到基因融合,但这些方法在识别驱动程序融合中仍存在局限性。另外,用于识别驱动基因融合的现有方法忽略了不同癌症之间的特异性,或者仅考虑了其在网络中的局部而非全局拓扑特征。在这里,我们提出了一种新的基于网络的方法,称为RWCFusion,以识别表型特定的癌症驱动基因融合。为了评估其性能,我们在35种癌症中使用了留一法交叉验证,对于整体癌症,AUC值为0.925,对于信号癌则为0.929。此外,我们将35种癌症分为血液学和实体性两大类,其中血液学的AUC最高,可达0.968。最后,我们将RWCFusion应用于乳腺癌,发现前13种基因融合体(例如BCAS3-BCAS4,NOTCH-NUP214,MED13-BCAS3和CARM-SMARCA4)已被证明是乳腺癌的驱动因素。此外,我们推断出其余10个候选基因融合物中的8个,例如SULF2-ZNF217,MED1-ACSF2和ACACA-STAC2,可能是乳腺癌的潜在驱动基因融合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号